Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2018-09-12 Share Issue/Capital Cha…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
LM-GLPG-UitgifteOphVoork-art596-12Sept2018-EN-SignedbyDeloitte.pdf
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled 'Statutory auditor's report in accordance with article 596 of the Belgian Company Code' concerning the 'Issuance of shares with cancellation of the preferential subscription right'. This report is provided by the statutory auditor (Deloitte) to validate the financial information in the Board's special report regarding a capital increase involving the cancellation of subscription rights. This specific function—an auditor's review of a board proposal related to capital structure changes—fits best under the 'Audit Report / Information' category (AR), as it is a standalone audit opinion on a specific corporate action, rather than a full annual report (10-K) or a general financing announcement (CAP). Although it relates to capital, its primary nature is an auditor's certification.
2018-09-12 English
LM-GLPG-UitgifteOphVoork-art596-12Sept2018-NL-SignedbyDeloitte.pdf
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled 'Verslag van de commissaris in het kader van artikel 596 van het Wetboek van vennootschappen - Uitgifte van aandelen met opheffing van het voorkeurrecht' (Commissioner's Report under Article 596 of the Companies Code - Issuance of shares with waiver of pre-emptive rights). This report is a formal opinion by an auditor (Deloitte) on the financial data provided by the Board regarding a proposed capital increase involving the waiver of shareholder pre-emptive rights. This specific type of report, which is an independent verification related to a significant corporate action (capital change/share issuance) but is not the full annual report (10-K) or a general audit report (AR), fits best under Capital/Financing Update (CAP) or potentially Audit Report/Information (AR). However, since the core subject is the verification of financial data supporting a capital structure change (issuance of shares with waiver of pre-emptive rights), it is most closely related to financing activities. Given the options, 'CAP' (Capital/Financing Update) is the most appropriate category as it directly concerns the mechanics and verification of a capital increase proposal, although it is a specific type of assurance report. If a more specific 'Capital Issuance Assurance Report' existed, it would be chosen. Comparing CAP and AR: AR is for standalone audit reports or stress tests. This is an assurance report tied directly to a financing event. Therefore, CAP is the better fit.
2018-09-12 Dutch
Madison_Board Report 596_ENG.pdf
Capital/Financing Update Classification · 95% confidence The document is explicitly titled "Special report of the board of directors in accordance with Article 596 of the Belgian Companies Code" concerning the "Cancellation of the preferential subscription rights of the existing shareholders in general within the framework of the proposed capital increase under the authorized capital." This document details a proposed capital increase, the rationale (funding R&D, strengthening cash position), the structure involving a public offering of New ADSs in the US, and the justification for cancelling pre-emptive rights. This content strongly aligns with corporate actions related to financing and capital structure changes, specifically detailing the mechanics of a share issuance proposal. While it discusses capital, it is a formal report justifying the action, not just a simple announcement of a dividend (DIV) or a general regulatory filing (RNS). It is a detailed report justifying a capital action, which fits best under Capital/Financing Update (CAP) as it is the core subject matter, although it is a formal report rather than a brief announcement. Given the depth and the focus on the mechanics of the capital increase and the cancellation of rights, it is a specific financing document. It is not a 10-K, IR, ER, or CT. It is a formal report detailing a capital action.
2018-09-12 English
Madison_Board Report 596_NED.pdf
Capital/Financing Update Classification · 98% confidence The document is a "Bijzonder verslag van de raad van bestuur overeenkomstig Artikel 596 van het Wetboek van Vennootschappen" (Special report of the board of directors pursuant to Article 596 of the Companies Code). The core subject is the proposed capital increase ("Kapitaalverhoging") involving the issuance of new shares/ADSs and the proposed cancellation of existing shareholders' pre-emptive rights ("opheffing van het voorkeurrecht"). This action relates directly to financing activities and capital structure changes. While it involves a report from the Board, its primary function is to justify and detail a specific financing/capital event. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a standard Annual Report (10-K), an Earnings Release (ER), or a general Investor Presentation (IP), but a specific legal/financial document detailing a capital raise proposal.
2018-09-12 Dutch
GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN FIRST PHASE 3 STUDY IN RHEUMATOID ARTHRITIS
Regulatory Filings Classification · 95% confidence The document is a press release, indicated by the structure, the inclusion of contact information for investors and media, and the explicit mention of 'Gereglementeerde informatie' (Regulated information) and forward-looking statements referencing SEC filings (like Form 20-F and 10-Q). The content details the positive results of a Phase 3 clinical trial (FINCH 2) for a drug (filgotinib) and announces that the full details will be presented at a future scientific conference. This format—a formal announcement of clinical trial results and associated data—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a detailed announcement of clinical trial data and not just a summary of quarterly financial performance (ER), and it is not a formal report itself (like 10-K or IR), it fits best as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were the slides themselves. Given the text nature, it is a press release announcing scientific/clinical progress, which often falls under RNS if no other specific category applies. However, since it is a detailed announcement of scientific/clinical progress, it is often categorized as an Investor Presentation (IP) if the intent is to inform investors about the drug pipeline, or RNS as a general regulatory announcement. Given the detailed data tables and scientific context, IP is a strong candidate, but RNS is the safest fallback for non-standard regulatory news. Since it is a press release announcing clinical trial results, which is a key piece of information for investors, and it is not a formal financial report, I will classify it as RNS as the most general regulatory announcement category, although IP is plausible if this text accompanied slides. Given the context of major clinical trial data release, RNS is appropriate for a regulatory announcement of this nature.
2018-09-12 English
GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN FIRST PHASE 3 STUDY IN RHEUMATOID ARTHRITIS
Regulatory Filings Classification · 95% confidence The document is a press release dated September 11, 2018, announcing that the Phase 3 study (FINCH 2) for the drug filgotinib met its primary and key secondary endpoints for treating rheumatoid arthritis. It contains detailed efficacy data tables, safety information, quotes from management, and forward-looking statements. This format—a formal announcement of clinical trial results intended for immediate public disclosure—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate news. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Proxy (DEF 14A), the most appropriate classification for a major, time-sensitive announcement of operational/clinical success is 'Earnings Release' (ER), as clinical trial milestones often accompany or substitute for traditional earnings announcements in biotech/pharma, or it could be classified as a general Regulatory Filing (RNS). Given the structure and content focusing on trial results and management commentary, ER is a strong fit, but since it is not explicitly an 'earnings' report, RNS (Regulatory Filings - the fallback for miscellaneous announcements) is also plausible. However, in the context of major corporate news releases, ER is often used for significant operational milestones that impact valuation. Given the high impact nature of Phase 3 success, I will lean towards ER as it communicates key performance indicators (clinical success) immediately, similar to how ER communicates financial KPIs. If ER is strictly for financial results, RNS is the fallback. Since this is a major clinical update, ER is the best fit among the specific options that aren't financial reports. If it were purely a notice that a report was coming, it would be RPA. Since it contains the results, ER is chosen.
2018-09-12 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.